HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device.

AbstractAIMS:
Atrial tachycardia and flutter frequently occur in association with atrial fibrillation and may be treated by overdrive pacing in patients who receive pacemakers with antitachycardia pacing (ATP) capabilities. The PITAGORA trial was a multi-centre, randomized, cross-over study aimed at comparing two different ATP modes for atrial tachyarrhythmia (AT) termination in patients suffering from sinus node disease (SND).
METHODS AND RESULTS:
One hundred and seventy-six patients (72 M, age 71+/-9 years) received a Medtronic AT500 pacemaker. All patients were on class IC or III antiarrhythmic drugs. After a 5-month observation period, 170 patients were randomized to either Ramp or Burst+ ATP therapy; 4 months later they crossed over. One hundred and fifty-seven patients completed the 13 months of follow-up; 114 (72.6%) suffered 6088 AT episodes. In 75 patients, 1904 AT episodes were treated and 934 (49.1%) successfully terminated. The median value of individual patients' ATP efficacy was 60%. Burst+ terminated 387 out of 873 AT episodes (44%) in 58 patients. Ramp terminated 547 out of 1031 AT episodes (53%, P<0.001) in 56 patients. Ramp efficacy was significantly (P<0.01) and directly correlated with AT cycle length (ATCL), whereas Burst+ efficacy was not. Ramp showed higher (P<0.001) termination efficacy than Burst+ for ATCL >240 ms. Quality of life, as measured by the EuroQoL questionnaire, and number of symptoms significantly improved in the overall population. This improvement was significantly higher in patients with ATP efficacy >60%.
CONCLUSION:
In patients suffering from SND and AT, Ramp therapy shows higher termination efficacy than Burst+ therapy in AT episodes with ATCL >240 ms. Further studies are required to show the impact of ATP on clinical outcomes.
AuthorsMichele Gulizia, Salvatore Mangiameli, Serafino Orazi, Giacomo Chiarandà, Giuseppe Boriani, Guglielmo Piccione, Nicolò DiGiovanni, Andrea Colletti, Calogero Puntrello, Gaetano Butera, Calogero Vasco, Ignazio Vaccaro, Giuseppe Scardace, Andrea Grammatico, PITAGORA (Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias) Investigators
JournalEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (Europace) Vol. 8 Issue 7 Pg. 465-73 (Jul 2006) ISSN: 1099-5129 [Print] England
PMID16798758 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Topics
  • Aged
  • Aged, 80 and over
  • Arrhythmia, Sinus (physiopathology, therapy)
  • Atrial Fibrillation (physiopathology, therapy)
  • Cardiac Pacing, Artificial (methods)
  • Chi-Square Distribution
  • Cross-Over Studies
  • Female
  • Humans
  • Italy
  • Least-Squares Analysis
  • Male
  • Middle Aged
  • Prospective Studies
  • Quality of Life
  • Statistics, Nonparametric
  • Tachycardia (physiopathology, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: